Lead Therapeutic Candidate - TTX-MC138
Targeting microRNA-10b - master regulator of metastasis
TransCode’s lead therapeutic candidate, TTX-MC138, is a targeted therapy designed to treat cancer patients with metastatic cancer, an area traditionally overlooked because, from a therapeutic perspective, non-metastatic and metastatic tumor cells are often viewed as being the same. However, despite significant efforts made in the past several years to decipher the genetic structure of primary tumors, there has been relatively limited attention given to comprehending the genetic makeup of metastatic tumors.
TransCode's promising therapeutic strategy relies on specific eradication of metastatic tumor cells– cells that have evolved from the primary tumor to escape into the circulation, survive during transit, and colonize distant organs.
TTX-MC138, our lead therapeutic candidate, has been shown to inhibit microRNA-10b
resulting in regression of disease without recurrence in pre-clinical studies.